RxDoctor Payments Data

Bhavin Patel, MD

Cardiovascular Disease · Maryville, TNNPI 1033344619

Payments from drug & device makers

$4,994in general payments, 2019–2025

Across 261 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$470
  • Pfizer$453
  • Actelion Pharmaceuticals US, Inc.$420
  • Abiomed$287
  • Johnson & Johnson$279
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,96699%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,994 in reported general payments places this provider in the 60th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$228,304
Medicare patients
1,249
Services billed
4,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban693$673,119
EntrestoSacubitril/Valsartan209$203,151
Repatha SureclickEvolocumab81$82,066
XareltoRivaroxaban96$78,314
JardianceEmpagliflozin29$39,567
FarxigaDapagliflozin Propanediol31$31,462
BrilintaTicagrelor26$20,127
CorlanorIvabradine Hcl17$9,513
Flecainide Acetate217$9,167
Ranolazine ErRanolazine67$6,465
Atorvastatin Calcium607$5,652
Metoprolol Succinate385$4,536
Ezetimibe172$2,937
Rosuvastatin Calcium187$2,221
Losartan Potassium228$1,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$453$673,119693 claims
NovartisEntresto$1,000$203,151209 claims
Johnson & JohnsonXarelto$279$78,31496 claims
AstraZenecaFarxiga, Brilinta$70$51,58957 claims
Boehringer IngelheimJardiance$68$39,56729 claims
AmgenCorlanor$90$9,51317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →